Andy Chen
Stock Analyst at Wolfe Research
(4.58)
# 917
Out of 4,457 analysts
67
Total ratings
66%
Success rate
29.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics | Maintained: Buy | $44 | $37.44 | +17.52% | 4 | Jun 14, 2026 | |
| ABVX ABIVAX Société Anonyme | Rated: Buy | $176 → $136 | $96.15 | +41.45% | 2 | Jun 3, 2026 | |
| VERA Vera Therapeutics | Maintained: Buy | $88 | $43.15 | +103.94% | 4 | Jun 2, 2026 | |
| PALI Palisade Bio | Initiated Coverage: Buy | $7 | $2.23 | +213.90% | 1 | Apr 8, 2026 | |
| AVTX Avalo Therapeutics | Initiated Coverage: Buy | $48 | $19.29 | +148.83% | 1 | Apr 8, 2026 | |
| DNTH Dianthus Therapeutics | Maintained: Buy | $98 | $95.68 | +2.42% | 1 | Apr 8, 2026 | |
| PHVS Pharvaris | Initiated Coverage: Buy | $42 | $34.71 | +21.00% | 1 | Apr 8, 2026 | |
| IMVT Immunovant | Maintained: Buy | $47 | $38.51 | +22.05% | 4 | Apr 6, 2026 | |
| MLTX MoonLake Immunotherapeutics | Upgraded: Buy | $24 | $19.91 | +20.54% | 5 | Mar 23, 2026 | |
| APGE Apogee Therapeutics | Initiated Coverage: Hold | n/a | $132.61 | - | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $527.28 | - | 2 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $548 | $499.65 | +9.68% | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $109.32 | - | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $912.46 | - | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $16.61 | - | 4 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $3.55 | +266.20% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $54 → $173 | $104.74 | +65.17% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $293.52 | - | 4 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $17.02 | n/a | 1 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $49 | $72.01 | n/a | 1 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $65.97 | n/a | 2 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $84 | $114.66 | n/a | 2 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $90.16 | n/a | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $92.49 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $36.94 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $19 | $25.55 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $18.79 | n/a | 1 | Jun 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $58 | $80.69 | n/a | 2 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $56.35 | n/a | 1 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $34.73 | n/a | 1 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $6.85 | n/a | 1 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $0.0001 | n/a | 2 | Aug 10, 2023 |
Celldex Therapeutics
Jun 14, 2026
Maintained: Buy
Price Target: $44
Current: $37.44
Upside: +17.52%
ABIVAX Société Anonyme
Jun 3, 2026
Rated: Buy
Price Target: $176 → $136
Current: $96.15
Upside: +41.45%
Vera Therapeutics
Jun 2, 2026
Maintained: Buy
Price Target: $88
Current: $43.15
Upside: +103.94%
Palisade Bio
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $2.23
Upside: +213.90%
Avalo Therapeutics
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $48
Current: $19.29
Upside: +148.83%
Dianthus Therapeutics
Apr 8, 2026
Maintained: Buy
Price Target: $98
Current: $95.68
Upside: +2.42%
Pharvaris
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $34.71
Upside: +21.00%
Immunovant
Apr 6, 2026
Maintained: Buy
Price Target: $47
Current: $38.51
Upside: +22.05%
MoonLake Immunotherapeutics
Mar 23, 2026
Upgraded: Buy
Price Target: $24
Current: $19.91
Upside: +20.54%
Apogee Therapeutics
Jan 7, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $132.61
Upside: -
Jan 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $527.28
Upside: -
Jan 6, 2026
Upgraded: Buy
Price Target: $548
Current: $499.65
Upside: +9.68%
Jan 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $109.32
Upside: -
Nov 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $912.46
Upside: -
Nov 11, 2025
Downgraded: Hold
Price Target: n/a
Current: $16.61
Upside: -
Nov 5, 2025
Initiated Coverage: Buy
Price Target: $13
Current: $3.55
Upside: +266.20%
Aug 14, 2025
Maintained: Buy
Price Target: $54 → $173
Current: $104.74
Upside: +65.17%
Aug 4, 2025
Upgraded: Hold
Price Target: n/a
Current: $293.52
Upside: -
Jun 16, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $17.02
Upside: n/a
Jun 16, 2025
Initiated Coverage: Buy
Price Target: $49
Current: $72.01
Upside: n/a
May 21, 2025
Reiterated: Buy
Price Target: $25
Current: $65.97
Upside: n/a
Mar 17, 2025
Maintained: Buy
Price Target: $84
Current: $114.66
Upside: n/a
Mar 17, 2025
Initiated Coverage: Buy
Price Target: $27
Current: $90.16
Upside: n/a
Feb 3, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $92.49
Upside: n/a
Feb 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $36.94
Upside: n/a
Feb 3, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $25.55
Upside: n/a
Jun 10, 2024
Rated: Buy
Price Target: $29
Current: $18.79
Upside: n/a
Apr 9, 2024
Upgraded: Buy
Price Target: $58
Current: $80.69
Upside: n/a
Feb 14, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $56.35
Upside: n/a
Feb 14, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $34.73
Upside: n/a
Oct 25, 2023
Maintained: Buy
Price Target: $4
Current: $6.85
Upside: n/a
Aug 10, 2023
Reiterated: Buy
Price Target: $60
Current: $0.0001
Upside: n/a